PAM50 GENETIC TEST IDENTIFIES TRIPLE-NEGATIVE BREAST CANCER PATIENTS WHO MAY BENEFIT FROM ADJUVANT CAPECITABINE
Patients with non-basal triple-negative breast cancer are those who benefit most from chemotherapy with oral capecitabine as adjuvant treatment, according to a new analysis of the patient population of the phase III clinical trial GEICAM/2003-11_CIBOMA/2004-01, called GEICAM/CIBOMA, carried out by GEICAM and the Ibero-American Coalition for Research in Breast Oncology (CIBOMA). The results of the study […]
